| abstract |
REFERS TO COMPOUNDS DERIVED FROM AMINOPYRAZOLE OF FORMULA (I) WHERE R1 IS H, HYDROXY, HALOGEN, CN, ALKYL (C1-C6), AMONG OTHERS; R2 IS H, HALOGEN, NITRO, HALOALKYL (C1-C4), AMONG OTHERS; R3 IS H, (C1-C5) ALKYL, ARYL (C6-C10) -ALKYL (C1-C6) OR HALO (C1-C4) ALKYL; R4 IS H, HALOGEN, (C1-C3) ALKYL, CN, AMONG OTHERS; A IS HETEROARYL OF 5 TO 10 MEMBERS OR ARYL (C6-C10). THE PREFERRED COMPOUNDS ARE: [5-AMINO-1- (2-METHYL-1H-BENZYMIDAZOLE-5-IL) -1H-PYRAZOLE-4-IL] - (1H-INDOL-2-IL) -METHANONE; [5-AMINO-1- (2-METHYL-1H-BENZYMIDAZOLE-5-IL) -1H-PYRAZOLE-4-IL] - (6-PYRROLIDIN-1-ILMETHYL-1H-INDOL-2-IL) -METHANONE; [5-AMINO-1- (2-METHYL-1H-BENZYMIDAZOL-5-IL) -1H-PYRAZOLE-4-IL] - [6- (4-HYDROXY-PIPERIDIN-1-ILMETYL) -1H-INDOL-2 -IL] -METHANONE; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE INHIBITORS OF THE KINASE OF THE FIBROBLASTIC GROWTH FACTOR RECEIVER FAMILY KINASE (FGFR), BEING USEFUL IN THE TREATMENT OF CANCER |